Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 7/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16017796 | 0.82 | CYP1A2 (0.42) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL16017792 | 0.79 | CYP1A2 (0.42) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL22866107 | 0.77 | CYP1A2 (0.55) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL16020460 | 0.77 | CYP2D6 (0.41) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL4408873 | 0.75 | CYP2D6 (0.50) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL19209667 | 0.75 | CA1 (0.45) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL19944669 | 0.75 | CYP1A2 (0.52) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL16017904 | 0.73 | CYP1A2 (0.40) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL18428106 | 0.72 | CYP2D6 (0.55) | CYP2D6CA1CA2CA7CTSK | |
| SCHEMBL16017850 | 0.72 | PRKCA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256694-A1 | STEROID ANTIBIOTIC CONJUGATES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256651-A1 | Cyclosporine A steroid conjugates | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256658-A1 | Antibiotic Conjugates | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256660-A1 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256666-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256696-A1 | Steroid conjugates | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256666-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | MMP17, NAALAD2, DNPEP | CYP2D6 101/4885CA1 1797/4885CA2 757/4885 |
| US-20140256694-A1 | STEROID ANTIBIOTIC CONJUGATES | CYP17A1, CYP21A2, HSD17B1 | CYP2D6 102/4885CA1 3368/4885CA2 2206/4885 |
| US-20140256660-A1 | ANTIBIOTIC CONJUGATES LINKED WITH STEROID DRUGS | CYP21A2, CYP17A1, CYP46A1 | CYP2D6 210/4885CA1 2586/4885CA2 1831/4885 |
| US-20140256658-A1 | Antibiotic Conjugates | NAALAD2, DNPEP, ENGASE | CYP2D6 206/4885CA1 3449/4885CA2 1706/4885 |
| US-20140256696-A1 | Steroid conjugates | CYP21A2, CYP17A1, HSD17B2 | CYP2D6 78/4885CA1 1054/4885CA2 1044/4885 |
| US-20140256651-A1 | Cyclosporine A steroid conjugates | CYP21A2, CHP1, CYP51A1 | CYP2D6 180/4885CA1 1241/4885CA2 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.